Floatz logo

vb15010

Neoplasms, Breast

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

890 Active assets in the Neoplasms, Breast cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Loratadine
Noha Mansour
Phase 2BB
VITAMIN D
University of Illinois at Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

vb15010 is also rated in:

biliary tract cancerDormant
CCC
Indicative ·
48 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
47 / 100
View asset →
ovarian neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →